Risk of SARS-CoV-2 Infection in Previously Infected and Non-Infected Cohorts of Health Workers at High Risk of Exposure
Sánchez-Montalvá, Adrián (Hospital Universitari Vall d'Hebron)
Fernandez-Naval, Candela (Vall d'Hebron Institut d'Oncologia)
Antón, Andrés (Vall d'Hebron Institut d'Oncologia)
Durà, Xavier (Hospital Universitari Vall d'Hebron)
Vimes, Alba (Hospital Universitari Vall d'Hebron)
Silgado, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Velásquez-Orozco, Fernando (Vall d'Hebron Institut d'Oncologia)
Espinosa-Pereiro, Juan (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Salvador, Fernando (Hospital Universitari Vall d'Hebron)
Pumarola Suñé, Tomàs (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Almirante Gragera, Benito (Hospital Universitari Vall d'Hebron)
Esperalba, Juliana (Vall d'Hebron Institut d'Oncologia)
Universitat Autònoma de Barcelona

Fecha:	2021
Resumen:	The objective of this study is to assess the risk of newly acquired RNA detection-proven SARS-CoV-2 infection after previous SARS-CoV-2 infection. This is a prospective study conducted from March to September 2020 in Barcelona, Spain. Healthcare workers caring for SARS-CoV-2 infected patients were divided in two cohorts: (a) previously RNA-proven SARS-CoV-2 infected cohort with mild symptoms (IC) and (b) healthy cohort (HC). Weekly SARS-CoV-2 RNA detection assays from nasopharyngeal swabs were performed. Serology status was assessed at the beginning and at the end of the study. Twenty participants were included in each group. The median age was 30 (IQR 27-34. 75) years, and 55% were female. The median time of follow up was 49 (IQR 49-51) days. Fifteen out of 246 (6%) nasopharyngeal swab samples were positive for SARS-CoV-2, all in the IC. The percentage of participants in the IC with a probable newly acquired SARS-CoV-2 RNA-proven infection was 20% (95% IC 5. 7-43. 6%) at the end of the 7-week follow up period. The incidence reinfection rate was 28. 6 (95% IC 7. 8-73. 2) cases per 1000 person-week. Despite detectable IgG antibodies against SARS-CoV-2 participants highly exposed to SARS-CoV-2 may develop a newly acquired SARS-CoV-2 RNA detection episode during the first months after the initial infection.
Ayudas:	Instituto de Salud Carlos III JE18/0002
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Reinfection ; SARS-CoV-2 ; Natural immunity ; Genome amplification diagnostic assays ; Serology
Publicado en:	Journal of clinical medicine, Vol. 10 (may 2021) , ISSN 2077-0383

DOI: 10.3390/jcm10091968
PMID: 34064314

10 p, 1.2 MB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados